| Novel |
CD79A
|
CD79a molecule |
- CD22 mediated BCR regulation
- Potential therapeutics for SARS
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
- Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
|
| Novel |
CDK18
|
cyclin dependent kinase 18 |
|
|
|
| Novel |
CHIT1
|
chitinase 1 |
- Digestion of dietary carbohydrate
- Neutrophil degranulation
|
- 2-acetylamino-2-deoxy-b-D-allopyranose
- 2-(Acetylamino)-2-Deoxy-6-O-Methyl-Alpha-D-Allopyranose
- Argifin
- Argadin
- Allosamizoline
|
|
| Novel |
CRB1
|
crumbs cell polarity complex component 1 |
|
|
- Leber congenital amaurosis (LCR)
- Retinitis pigmentosa (RP)
|
| Novel |
CSNK1E
|
casein kinase 1 epsilon |
- WNT mediated activation of DVL
- Regulation of PLK1 Activity at G2/M Transition
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Anchoring of the basal body to the plasma membrane
- Major pathway of rRNA processing in the nucleolus and cytosol
- Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
- AURKA Activation by TPX2
- The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex
- Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
|
|
|
| Novel |
EIF2D
|
eukaryotic translation initiation factor 2D |
|
|
|
| Novel |
F13B
|
coagulation factor XIII B chain |
- Common Pathway of Fibrin Clot Formation
|
- Zinc
- Catridecacog
- Thrombin
- Human thrombin
- Zinc acetate
|
|
| Novel |
GRB7
|
growth factor receptor bound protein 7 |
- GRB7 events in ERBB2 signaling
- Signaling by SCF-KIT
- Downstream signal transduction
- Tie2 Signaling
- RET signaling
- RND1 GTPase cycle
|
|
|
| Novel |
IL10
|
interleukin 10 |
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
- CD163 mediating an anti-inflammatory response
- FCGR3A-mediated IL10 synthesis
- Signaling by ALK fusions and activated point mutants
|
|
- Graft-versus-host disease
- Allograft rejection
|
| Novel |
MYOG
|
myogenin |
- Myogenesis
- Myogenesis
- TGFBR3 expression
|
|
|
| Novel |
PAICS
|
phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase |
- Purine ribonucleoside monophosphate biosynthesis
|
|
|
| Novel |
VAV1
|
vav guanine nucleotide exchange factor 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- NRAGE signals death through JNK
- Regulation of actin dynamics for phagocytic cup formation
- Constitutive Signaling by Aberrant PI3K in Cancer
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- CD28 dependent Vav1 pathway
- G alpha (12/13) signalling events
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- VEGFR2 mediated vascular permeability
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- RHOA GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOG GTPase cycle
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Regulation of signaling by CBL
- FCGR3A-mediated phagocytosis
- FCGR3A-mediated phagocytosis
- Potential therapeutics for SARS
- Azathioprine ADME
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
|
| Novel |
VBP1
|
VHL binding protein 1 |
- Prefoldin mediated transfer of substrate to CCT/TriC
|
|
|
|
ANP32A
|
acidic nuclear phosphoprotein 32 family member A |
- HuR (ELAVL1) binds and stabilizes mRNA
|
|
|
|
CD1D
|
CD1d molecule |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
- cis-tetracosenoyl sulfatide
|
|
|
CD2
|
CD2 molecule |
- Cell surface interactions at the vascular wall
|
|
|
|
CD22
|
CD22 molecule |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- CD22 mediated BCR regulation
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Epratuzumab
- Inotuzumab ozogamicin
- Moxetumomab pasudotox
|
|
|
CD247
|
CD247 molecule |
|
- Muromonab
- Teclistamab
- Odronextamab
|
|
|
CD28
|
CD28 molecule |
- PIP3 activates AKT signaling
- Nef mediated downregulation of CD28 cell surface expression
- Constitutive Signaling by Aberrant PI3K in Cancer
- Co-stimulation by CD28
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
|
CD4
|
CD4 molecule |
- Alpha-defensins
- Nef Mediated CD4 Down-regulation
- Binding and entry of HIV virion
- Vpu mediated degradation of CD4
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- Co-inhibition by PD-1
- Other interleukin signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- Antithymocyte immunoglobulin (rabbit)
- Clenoliximab
- Ibalizumab
|
|